Delcath stock.

Get the latest Delcath Systems, Inc. (DCTH) stock news and headlines to help you in your trading and investing decisions.Find real-time DCTH - Delcath Systems Inc stock quotes, company profile, news and forecasts from CNN Business.-----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: [email protected] originator-key-asymmetric ...Dec 8, 2022 · Delcath will issue and sell 1,448,889 shares of its common stock (the "Common Stock") at a price per share of $2.90, or, in lieu of shares of Common Stock, 692,042 pre-funded warrants to purchase ...

Delcath is dedicated to revolutionizing the treatment of patients with cancer in their liver. Delcath Systems, Inc. is a commercial-stage interventional oncology company aiming to be the leader in targeted, safe and effective minimally-invasive treatments for patients with cancers in the liver.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY. DCTH - Delcath Systems Inc - Stock screener for investors and traders, financial visualizations.

DCTH | November 13, 2023. NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023.Nov 15, 2023 · Delcath Systems, Inc. (NASDAQ: DCTH) observed an upward trajectory in its stock value during the extended trading session on Tuesday. The after-hours market saw a 6.22% surge, elevating Delcath stock to $2.39. This positive movement partially offset the earlier 24.50% decline, settling the regular session at $2.25. The surge was instigated by ... Aug 15, 2023 · Crazy to sell under $8.5-9 "Delcath Systems price target raised to $18 from $14 at Canaccord Canaccord raised the firm's price target on Delcath Systems to $18 from $14 and keeps a Buy rating on ... Delcath Systems has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 542.86% from the latest price.

Nov 22, 2023 · 15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: DCTH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Aug 12, 2023 · Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ... Dec 1, 2023 · Earnings for Delcath Systems are expected to grow in the coming year, from ($2.43) to ($1.45) per share. Delcath Systems has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 25th, 2024 based off prior year's report dates. Read More. May 17, 2022 · Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ... The FDA approved Delcath Systems Inc's DCTH HEPZATO KIT (melphalan/Hepatic Delivery System).. The approval is as a liver-directed treatment for adult patients with metastatic uveal melanoma with ...Get the latest Delcath Systems, Inc. (DCTH) stock news and headlines to help you in your trading and investing decisions. Nov 17, 2023 · Delcath is a very volatile stock. Personally, I like to look at the long term when everyone else is looking at day to day stock prices. However, this quick trading environment makes it pretty ... Find the latest Delcath Systems (DCTH) discussion and analysis from iHub's community of investors.

PROPOSAL 2: APPROVAL OF DELCATH SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN . On August 5, 2021, the Company’s Board of Directors adopted the Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, or the ESPP, subject to stockholder approval. The Board unanimously recommends that our stockholders vote to …View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ. Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ...Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of an article ...

united states. securities and exchange commission. washington, d.c. 20549 . form 10-q

Delcath Systems is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying. Insiders at Delcath Systems Have Bought Stock Recently .united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath ...Get breaking news and analysis on Delcath Systems, Inc. (DCTH) stock, price Delcath Systems, Inc. View real- time stock prices and stock quotes for a full financial overview. We cover the latest Delcath Systems headlines and breaking news impacting Delcath Systems stock performance. YTD % Chg -57.18. 1 Year % Chg -95.87. Market …52 Week Low. $2.25. Data as of November 24, 2023 1:00 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. undefined. See a complete list of stock information for Delcath systems and get more info from our dedicated team revolutionizing the treatment of cancer patients.Get the latest Delcath Systems, Inc. (DCTH) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more.52 Week Low Date 10/13/22. Market Cap 63.773M. Shares Out 10.62M. 10 Day Average Volume 0.02M. Dividend -. Dividend Yield -. Beta 0.85. YTD % Change 66.8.Oncology-focused healthcare equipment maker Delcath Systems ( NASDAQ: DCTH) added ~66% pre-market Tuesday after announcing the FDA approval of its Hepzato Kit device as a treatment for a type of ...May 12, 2023 · Delcath is in the process of completing its customary quarter-end close and review procedures, including certain valuation work associated with the issuance of warrants and preferred stock in ...

Nov 6, 2023 · On Friday, Delcath Systems Inc [NASDAQ:DCTH] saw its stock fall -2.50% to $3.12. On the same session, the stock had its day’s lowest price of $3.05, but rose to a high of $3.32. Over the last five days, the stock has lost -4.88%. Delcath Systems Inc shares have fallen nearly -13.33% since the year began.

Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan ...

Complete Delcath Systems Inc. stock information by Barron's. View real-time DCTH stock price and news, along with industry-best analysis.DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) ROBERT B. LADD ...Aug 12, 2023 · Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ... NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material …Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announces that ...POINT72 ASSET MANAGEMENT LP Bought 717.7 Thousand shares of Delcath Systems Inc. 9/30/2023, STONEPINE CAPITAL MANAGEMENT LLC Bought 307.5 Thousand shares of ...Get the latest Delcath Systems Inc (DCTH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …DCTH Stock 12 Months Forecast. $18.33. (536.46% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Delcath Systems in the last 3 months. The average price target is $18.33 with a high forecast of $21.00 and a low forecast of $16.00. The average price target represents a 536.46% change from the last price of $2.88.

No changes to the price of Delcath Systems stock on the last trading day (Friday, 7th Feb 2020). During the last trading day the stock fluctuated 0% from a day low at $10.25 to a day high of $10.25.The price has fallen in 5 of the last 10 days and is down by -39.71% for this period.Established Date: 1988. Delcath Systems, Inc. is an interventional oncology company, which is focused on the treatment of primary and metastatic liver cancers. The Company's lead product candidate ...Laddcap Value Partners LP today announced that it issued the following letter to Delcath Systems Inc.'s (Nasdaq: DCTH) stockholders. -0- Laddcap Value Partners LPInstagram:https://instagram. mid america apartment communities incbuy stock in applepandg stock dividendmotleyfoo Delcath Systems, Inc. DCTH shares soared 6.6% in the last trading session to close at $11.72. The move was backed by solid volume with far more shares changing hands than in a normal session.Total stock market funds have a wider scope than the S&P 500. This index tracks 500 of the largest publicly-traded U.S. companies, accounting for around 80% of the market capitalization of the U.S ... mtb commercial servicesbest brokers for bonds Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ...Oncology-focused healthcare equipment maker Delcath Systems (DCTH) announced Monday that the FDA accepted its resubmitted new drug application ((NDA)) for the HEPZATO Kit for... best tool to track stock portfolio -----begin privacy-enhanced message----- proc-type: 2001,mic-clear originator-name: [email protected] originator-key-asymmetric ...0001193125-15-375676.txt : 20151112 0001193125-15-375676.hdr.sgml : 20151112 20151112161435 accession number: 0001193125-15-375676 conformed submission type: 424b3 public document count: 1 filed as of date: 20151112 date as of change: 20151112 filer: company data: company conformed name: delcath systems, inc. central index key: …